MXPA98002434A - Animales transgenicos para xenotrasplante con rechazo reducido de anticuerpos mediados. - Google Patents

Animales transgenicos para xenotrasplante con rechazo reducido de anticuerpos mediados.

Info

Publication number
MXPA98002434A
MXPA98002434A MXPA98002434A MX9802434A MXPA98002434A MX PA98002434 A MXPA98002434 A MX PA98002434A MX PA98002434 A MXPA98002434 A MX PA98002434A MX 9802434 A MX9802434 A MX 9802434A MX PA98002434 A MXPA98002434 A MX PA98002434A
Authority
MX
Mexico
Prior art keywords
transgenic animals
cells
gal
antibody
organs
Prior art date
Application number
MXPA98002434A
Other languages
English (en)
Inventor
Sharma Ajay
Original Assignee
Bioscience 2002 Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioscience 2002 Llc filed Critical Bioscience 2002 Llc
Publication of MXPA98002434A publication Critical patent/MXPA98002434A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/108—Swine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A01K2267/025—Animal producing cells or organs for transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Un metodo de xenotransplante de organos, tejidos y componentes de celulas no disponibles, que reduce o evita el rechazo de anticuerpo mediados, incluyendo el rechazo hiperagudo, se procura producir animales transgenicos que expresen por lo menos una enzima que reduzca o evite el nivel de antigeno Al (1,3) Al o al epitope, y por lo menos un componente inhibidor como CD59, DAF y/o MCP. Los animales transgenicos que expresan tanto una enzyma reductora de al epitome, como un complemento inhibidor, ocultaran o tendran niveles reducidos de gel epitome y tendran menso propension a producir un rechazo de anticuerpo mediado despues del transplante, y la expresion del complemento inhibidor suprime tambien la activacion complementaria y reduce una reaccion inmune severa despues del transplante de los organos, celulas o componentes no disponibles de animales transgenicos producidos para dicho fin. Adicionalmente, se proveen animales transgenicos que expresan una pluralidad de complementos inhibidores u otras proteinas de un sitio de genes en un solo sitio de integracion. La presente invencion es, por lo tanto, ya que provee organos xenogenicos, tejidos, celulas y componentes no disponibles que pueden ser transplantados de manera segura y efectiva a humanos con una reduccion o eliminacion del rechazo de anticuerpos mediados a un punto que no era posible previamente, y que reducira significativamente la necesidad de obtener organos, tejidos, celulas o componentes no disponibles de donadores humanos o primates.
MXPA98002434A 1995-09-27 1996-09-23 Animales transgenicos para xenotrasplante con rechazo reducido de anticuerpos mediados. MXPA98002434A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US446195P 1995-09-27 1995-09-27
US08/675,773 US6166288A (en) 1995-09-27 1996-07-03 Method of producing transgenic animals for xenotransplantation expressing both an enzyme masking or reducing the level of the gal epitope and a complement inhibitor
PCT/US1996/015255 WO1997012035A2 (en) 1995-09-27 1996-09-23 Transgenic animals for xenotransplantation with reduced antibody-mediated rejection

Publications (1)

Publication Number Publication Date
MXPA98002434A true MXPA98002434A (es) 2005-04-29

Family

ID=26673032

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA98002434A MXPA98002434A (es) 1995-09-27 1996-09-23 Animales transgenicos para xenotrasplante con rechazo reducido de anticuerpos mediados.

Country Status (10)

Country Link
US (1) US6166288A (es)
EP (1) EP0853665A2 (es)
JP (1) JP2001517924A (es)
CN (1) CN1278299A (es)
AU (1) AU727546B2 (es)
BR (1) BR9610843A (es)
CA (1) CA2233040A1 (es)
IL (1) IL123791A0 (es)
MX (1) MXPA98002434A (es)
WO (1) WO1997012035A2 (es)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331658B1 (en) * 1993-04-20 2001-12-18 Integris Baptist Medical Center, Inc. Genetically engineered mammals for use as organ donors
US6231608B1 (en) * 1995-06-07 2001-05-15 Crosscart, Inc. Aldehyde and glycosidase-treated soft and bone tissue xenografts
DE69734999T2 (de) * 1996-05-17 2006-09-21 Nippon Meat Packers, Inc. Promotoren von komplementinhibitoren des schweines.
US6455037B1 (en) * 1996-11-01 2002-09-24 Mount Sinai School Of Medicine Of The City University Of New York Cells expressing an αgala nucleic acid and methods of xenotransplantation
US6011197A (en) 1997-03-06 2000-01-04 Infigen, Inc. Method of cloning bovines using reprogrammed non-embryonic bovine cells
US6825395B1 (en) 1997-07-14 2004-11-30 Nippon Meat Packers, Inc. Transgenic non-human mammals expressing the human complement inhibitor (DAF/CD55)
CA2248971A1 (en) * 1997-10-31 1999-04-30 Kyowa Hakko Kogyo Co., Ltd. .beta.1, 3-n-acetylglucosaminyltransferase, dna encoding it and its use
US6383732B1 (en) * 1999-02-11 2002-05-07 Crosscart, Inc. Method of preparing xenograft heart valves
GB9807520D0 (en) * 1998-04-09 1998-06-10 Univ Wales Medicine Modified biological material
US6197294B1 (en) 1998-10-26 2001-03-06 Neurotech S.A. Cell surface molecule-induced macrophage activation
US6700037B2 (en) 1998-11-24 2004-03-02 Infigen, Inc. Method of cloning porcine animals
US6258998B1 (en) 1998-11-24 2001-07-10 Infigen, Inc. Method of cloning porcine animals
US6267786B1 (en) * 1999-02-11 2001-07-31 Crosscart, Inc. Proteoglycan-reduced soft tissue xenografts
US7005279B1 (en) * 1999-06-29 2006-02-28 Kyowa Hakko Kogyo Co., Ltd. Process for producing carbohydrates using β 1,3-N-acetyl-glucosaminyltransferase
US7074983B2 (en) 1999-11-19 2006-07-11 Kirin Beer Kabushiki Kaisha Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin
US7414170B2 (en) 1999-11-19 2008-08-19 Kirin Beer Kabushiki Kaisha Transgenic bovines capable of human antibody production
US7820878B2 (en) 1999-11-19 2010-10-26 Kyowa Hakko Kirin Co., Ltd. Production of ungulates, preferably bovines that produce human immunoglobulins
AU2001261650A1 (en) * 2000-05-15 2001-11-26 Geron Corporation Ovine tissue for xenotransplantation
US7485769B2 (en) * 2000-08-25 2009-02-03 Nippon Meat Packers, Inc. Transgenic mammals
ES2392508T3 (es) * 2001-02-20 2012-12-11 Intrexon Corporation Receptores X retinoides quiméricos y su uso en un sistema inducible de expresión génica basado en receptores de ecdisona novedoso
US7126039B2 (en) 2001-03-21 2006-10-24 Geron Corporation Animal tissue with carbohydrate antigens compatible for human transplantation
AU2002308533B2 (en) * 2001-04-30 2007-07-19 Rbc Biotechnology, Inc Modified organs and cells for xenotransplantation
US20050108780A1 (en) * 2002-01-24 2005-05-19 Erasmus University Intracellular antibodies for a retrovirus protein
EP1534066A4 (en) 2002-08-14 2008-01-02 Immerge Biotherapeutics Inc CELLS WITHOUT ALPHA (1,3) -GALACTOSYLTRANSFERASE, METHODS OF SELECTION, AND PORK HAVING ALPHA (1,3) -GALACTOSYLTRANSFERASE THUS OBTAINED
AU2003290689A1 (en) 2002-11-08 2004-06-03 Kyowa Hakko Kirin Co., Ltd. Transgenic ungulates having reduced prion protein activity and uses thereof
US7514593B2 (en) * 2003-05-30 2009-04-07 The University Of North Carolina At Chapel Hill Animal model for chronic obstructive pulmonary disease and cystic fibrosis
EP1639083A4 (en) * 2003-06-06 2008-05-28 Univ Pittsburgh GENE OF CMP-N-ACETYLNEURAMIC ACID HYDROXYLASE FROM PIG
EP2578676A1 (en) 2003-06-20 2013-04-10 Axiogenesis Ag Tissue modeling in multi- or pluripotent cell systems
WO2005009134A1 (en) * 2003-07-21 2005-02-03 Lifecell Corporation ACELLULAR TISSUE MATRICES MADE FROM GALACTOSE α-1,3-GALACTOSE-DEFICIENT TISSUE
US7420099B2 (en) 2004-04-22 2008-09-02 Kirin Holdings Kabushiki Kaisha Transgenic animals and uses thereof
CA2565986A1 (en) * 2004-05-07 2005-11-24 University Of Pittsburgh Of The Commnonwealth System Of Higher Education Porcine forssman synthetase protein, cdna, genomic organization, and regulatory region
EP1745144B1 (en) 2004-05-11 2010-12-01 Axiogenesis Ag Assay for drug discovery based on in vitro differentiated cells
US20060130157A1 (en) 2004-10-22 2006-06-15 Kevin Wells Ungulates with genetically modified immune systems
CA2909775A1 (en) * 2005-08-09 2007-03-29 Revivicor, Inc. Transgenic ungulates expressing ctla4-ig and uses thereof
WO2007134134A2 (en) 2006-05-09 2007-11-22 Lifecell Corporation Reinforced biological tissue
US7663019B2 (en) * 2006-05-24 2010-02-16 North Carolina State University Transgenic snakes and methods of making
US8124831B2 (en) * 2006-07-06 2012-02-28 Duke University Transgenic mice carrying functional single nucleotide polymorphisms in brain-specific tryptophan hydroxylase
WO2009009620A2 (en) 2007-07-10 2009-01-15 Lifecell Corporation Acellular tissue matrix compositions for tissue repair
WO2009069986A2 (en) * 2007-11-30 2009-06-04 Korea Research Institute Of Bioscience And Biotechnology Genetically-modified cell line for producing cloned miniature pigs for xenotransplantation and method for preparing the same.
EP2280740B1 (en) 2008-06-06 2015-04-01 Lifecell Corporation Elastase treatment of tissue matrices
ES2548377T3 (es) 2008-10-27 2015-10-16 Revivicor, Inc. Ungulados inmunodeprimidos
JP5784500B2 (ja) 2008-11-21 2015-09-24 ライフセル コーポレーションＬｉｆｅＣｅｌｌ Ｃｏｒｐｏｒａｔｉｏｎ 強化型生物由来物質
US8986377B2 (en) 2009-07-21 2015-03-24 Lifecell Corporation Graft materials for surgical breast procedures
ES2449890T3 (es) * 2009-09-02 2014-03-21 Lifecell Corporation Injertos vasculares obtenidos de matrices de tejido acelular
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
WO2011068778A1 (en) 2009-12-03 2011-06-09 Lifecell Corporation Nerve treatment devices and methods
CA2786228C (en) 2010-02-19 2018-02-06 Lifecell Corporation Abdominal wall treatment devices
WO2011119804A2 (en) 2010-03-25 2011-09-29 Lifecell Corporation Preparation of regenerative tissue scaffolds
CN103068413B (zh) 2010-07-08 2015-12-16 生命细胞公司 用于使组织基质成形的方法
EP3597226A1 (en) 2010-08-10 2020-01-22 Lifecell Corporation Regenerative tissue scaffolds
ES2788749T3 (es) 2010-08-26 2020-10-22 Lifecell Corp Métodos pasivos para mallas biológicas antimicrobianas
US20120148542A1 (en) 2010-12-10 2012-06-14 Lifeline Scientific, Inc. Machine perfusion with complement inhibitors
ES2680636T3 (es) * 2011-02-14 2018-09-10 Revivicor Inc. Cerdos genéticamente modificados para xenotrasplante de xenoinjertos vascularizados y derivados de los mismos
US8637067B1 (en) 2011-03-10 2014-01-28 Lifecell Corporation Elastic tissue matrix derived hydrogel
WO2012142419A1 (en) 2011-04-14 2012-10-18 Lifecell Corporation Regenerative materials
US10207025B2 (en) 2011-04-28 2019-02-19 Lifecell Corporation Method for enzymatic treatment of tissue products
SG194098A1 (en) 2011-04-28 2013-11-29 Lifecell Corp Method for enzymatic treatment of tissue products
US9238793B2 (en) 2011-04-28 2016-01-19 Lifecell Corporation Method for enzymatic treatment of tissue products
US20130121970A1 (en) 2011-11-10 2013-05-16 Lifecell Corporation Method for elimination of space through tissue approximation
AU2012335991B2 (en) 2011-11-10 2016-02-18 Lifecell Corporation Device for tendon and ligament treatment
EP2793965B1 (en) 2011-12-20 2019-02-20 LifeCell Corporation Flowable tissue products
AU2012355463C1 (en) 2011-12-20 2016-09-22 Lifecell Corporation Sheet tissue products
EP3461508A1 (en) 2012-01-24 2019-04-03 LifeCell Corporation Elongated tissue matrices
EP3488878A1 (en) 2012-03-08 2019-05-29 LifeCell Corporation Enzyme-activated collagen and tissue matrices
CA2871665A1 (en) 2012-04-24 2013-10-31 Lifecell Corporation Flowable tissue matrices
ES2749178T3 (es) 2012-04-24 2020-03-19 Lifecell Corp Matrices de tejido funcionalizado
ES2676043T3 (es) 2012-07-05 2018-07-16 Lifecell Corporation Colectores de drenaje tisulares
CA2913398C (en) 2012-07-06 2021-04-20 Lifecell Corporation Decellularized muscle matrix
WO2014052376A1 (en) 2012-09-26 2014-04-03 Lifecell Corporation Processed adipose tissue
US20140115728A1 (en) 2012-10-24 2014-04-24 A. Joseph Tector Double knockout (gt/cmah-ko) pigs, organs and tissues
US9592254B2 (en) 2013-02-06 2017-03-14 Lifecell Corporation Methods for localized modification of tissue products
CN103284797B (zh) * 2013-05-30 2016-06-29 美合实业（苏州）有限公司 一种内置消毒清洗装置的全科诊疗仪
EP3030272B1 (en) 2013-09-05 2019-05-29 LifeCell Corporation Method for enzymatic treatment of tissue products
AU2014341866B2 (en) 2013-11-04 2018-07-05 Lifecell Corporation Methods of removing alpha-galactose
NZ726602A (en) 2014-05-05 2024-05-31 Regeneron Pharmaceuticals Inc Humanized c5 and c3 animals
WO2016025666A1 (en) 2014-08-14 2016-02-18 Lifecell Corporation Tissue matrices and methods of treatment
JP2017536814A (ja) 2014-10-22 2017-12-14 インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレイションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 異種移植に好適なトランスジェニックブタ
US10850008B2 (en) 2015-12-11 2020-12-01 Lifecell Corporation Methods and systems for stiffening of tissue for improved processing
CA3013296A1 (en) 2016-02-11 2017-08-17 Lifecell Corporation Methods for stabilizing collagen-containing tissue products against enzymatic degradation
WO2017210109A1 (en) 2016-06-03 2017-12-07 Lifecell Corporation Methods for localized modification of tissue products
CA3029579A1 (en) 2016-07-05 2018-01-11 Lifecell Corporation Tissue matrices incorporating multiple tissue types
AU2017382173A1 (en) 2016-12-22 2019-06-06 Lifecell Corporation Devices and methods for tissue cryomilling
WO2018118862A1 (en) 2016-12-23 2018-06-28 Lifecell Corporation Injectable hydrogels and applications thereof
AU2017382264A1 (en) 2016-12-23 2019-07-04 Lifecell Corporation Injectable polyurethanes and applications thereof
AU2018212908A1 (en) 2017-01-30 2019-08-08 Lifecell Corporation Transglutaminase treated products
CA3051245A1 (en) 2017-01-30 2018-08-02 Lifecell Corporation Tissue matrix materials and enzymatic adhesives
CN110573188B (zh) 2017-01-30 2022-02-01 生命细胞公司 包括肌肉基质的装置以及生产方法和用途
CN107099513B (zh) * 2017-06-22 2020-07-14 北京邦卓生物科技有限公司 一种共表达ndv hn和ibdv vp2基因的hvt的构建及其应用
EP3942298A4 (en) * 2019-03-21 2022-12-21 The UAB Research Foundation METHOD OF INCREASING CELLULAR SENSITIVITY TO COMPLEMENT-MEDIATED LYSIS
US11266129B2 (en) 2019-11-05 2022-03-08 Versiti Blood Research Institute Foundation, Inc. Murine model of fetal/neonatal alloimmune thrombocytopenia
JP2023500896A (ja) 2019-11-05 2023-01-11 ヴァーシティ ブラッド リサーチ インスティテュート ファウンデーション， インコーポレイテッド 胎児／新生児同種抗体血小板減少症のマウスモデル

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) * 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
MY107433A (en) * 1989-10-12 1995-12-30 Imutran Ltd Modiefied biological material.
US5324663A (en) * 1990-02-14 1994-06-28 The Regents Of The University Of Michigan Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures
ATE237682T1 (de) * 1991-07-15 2003-05-15 Oklahoma Med Res Found Universale spenderzellen
EP0662125A1 (en) * 1992-09-22 1995-07-12 Dnx Biotherapeutics, Inc. Delivery of proteins by intermembrane transfer for preaccommodation of xenogeneic organ transplants and other purposes
AU685433B2 (en) * 1993-02-12 1998-01-22 Regents Of The University Of Minnesota Pulmonary administration of sCR1 and other complement inhibitory proteins
US5750176A (en) * 1994-03-09 1998-05-12 Abbott Laboratories Transgenic non-human mammal milk comprising 2'-fucosyl-lactose
ATE395418T1 (de) * 1994-04-13 2008-05-15 Biotransplant Inc Alpha(1,3)galactosyltransferase-negatives schwein
EP0769902A4 (en) * 1994-06-15 2001-02-28 Alexion Pharma Inc METHODS FOR REDUCING THE ACUTE REJECTION OF HETEROGRAFTS
AUPM772494A0 (en) * 1994-08-30 1994-09-22 Austin Research Institute, The Improvements in production of proteins in host cells
GB9421464D0 (en) * 1994-10-25 1994-12-07 Imutran Ltd Recombinant DNA

Also Published As

Publication number Publication date
WO1997012035A2 (en) 1997-04-03
IL123791A0 (en) 1998-10-30
AU727546B2 (en) 2000-12-14
EP0853665A2 (en) 1998-07-22
AU7117096A (en) 1997-04-17
US6166288A (en) 2000-12-26
CA2233040A1 (en) 1997-04-03
CN1278299A (zh) 2000-12-27
BR9610843A (pt) 1999-07-13
JP2001517924A (ja) 2001-10-09
WO1997012035A3 (en) 1997-06-12

Similar Documents

Publication Publication Date Title
MXPA98002434A (es) Animales transgenicos para xenotrasplante con rechazo reducido de anticuerpos mediados.
Platt et al. Acute vascular rejection
Akizuki et al. Expression of autoimmunity by NZBNZW marrow
Braun et al. Mediation of acute but not chronic rejection of MHC-incompatible rat kidney grafts by alloreactive CD4 T cells activated by the direct pathway of sensitization
EP0438053A1 (en) Durable engraftment and development of human hematopoietic lineages in normal mammals
EP0755402A4 (en) NEGATIVE PIG FOR ALPHA (1,3) GALACTOSYLTRANFERASE
EP0661980A4 (en) METHOD AND COMPOSITIONS TO OBTAIN ANTIBODY-MEDIATED REPELLATION OF XENOGENIC TRANSPLANTS.
MY107433A (en) Modiefied biological material.
EP0700297A4 (en) SUBSTITUTION TOLEROGENESIS FOR THE DEVELOPMENT OF XENOGRAFT TOLERANCE
PT941329E (pt) Metodo para prevenir a rejeicao de enxertos em transplantacao e para produzir uma celula-hospedeiro para terapia genetica universal utilizando activacao de linfocitos (lag-3)
GB1186833A (en) Improvements in or relating to the Propogation of Roses
MÖLLER PROLONGED SURVIVAL OF ALLOGENEIC:(HOMOLOGOUS) NORMAL TISSUES IN ANTISERUM-TREATED RECIPIENTS
Ross et al. Blood transfusion and organ transplantation
IM et al. MODIFICATION OF GRAFT-VERSUS-HOST DISEASE BY NEURAMINIDASE TREATMENT OF DONOR CELLS DECREASED TOLEROGENICITY OF NEURAMINIDASE-TREATED CELLS
AU6733896A (en) Transferrin glycans composition for the induction of immune tolerance
AU1256495A (en) Method and composition for transfer of active tumor-specific immunization from an immunized allogeneic bone marrow donor
Rodger et al. The enigma of the fetal graft
Ioachim et al. Antigenic deletion and malignant enhancement induced in lymphoma cells by passage through X-irradiated hosts
AU2790497A (en) Promoters for swine complement inhibitors
Seller Animal models for bone-marrow transplantation.
Krolak et al. Immunohistochemical Localization of Adenosine 3′: 5′-Cyclic Monophosphate in Female Ixodid Tick Amblyomma americanum (L.) Salivary Glands
O'Brien et al. Description of chlamydia-like micro-organisms in Hydra viridis and an initial characterization of the relationship between micro-organisms and host.
CA2254889A1 (en) A promoter gene for a porcine complement inhibitor
Voisin Immune agents of the facilitation reaction. Their possible role in protection of the placental allograft
White Kidney and Skin Allografts

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: BIOSCIENCE 2002 LLC

FA Abandonment or withdrawal